The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature
Authors:
- 22 December 2016
- journal article
- review article
- Published by Springer Nature in Journal of Neurology
- Vol. 264 (3) , 453-466
Abstract
Background It has long been known that the majority of patients with multiple sclerosis (MS) display an intrathecal, polyspecific humoral immune response to a broad panel of neurotropic viruses. This response has measles virus, rubella virus and varicella zoster virus as its most frequent constituents and is thus referred to as the MRZ reaction (MRZR). Objective Re-evaluation of the specificity of MRZR as a marker of MS. Methods Structured review of the existing English-, German- and Spanish-language literature on MRZR testing, with evaluation of MRZR in a cohort of 43 unselected patients with MS and other neurological diseases as a proof of principle. Results A positive MRZ reaction, defined as a positive intrathecal response to at least two of the three viral agents, was found in 78% of MS patients but only in 3% of the controls (p < 0.00001), corresponding to specificity of 97%. Median antibody index values were significantly lower in non-MS patients (measles, p < 0.0001; rubella, p < 0.006; varicella zoster, p < 0.02). The 30 identified original studies on MRZR reported results from 1478 individual MRZR tests. A positive MRZR was reported for 458/724 (63.3%) tests in patients with MS but only for 19/754 (2.5%) tests in control patients (p < 0.000001), corresponding to cumulative specificity of 97.5% (CI 95% 96–98.4), cumulative sensitivity of 63.3% (CI 95% 59.6–66.8) (or 67.4% [CI 95% 63.5–71.1] in the adult MS subgroup), a positive likelihood ratio of 25.1 (CI 95% 16–39.3) and a negative likelihood ratio of 0.38 (CI 95% 0.34–0.41). Of particular note, MRZR was absent in 52/53 (98.1%) patients with neuromyelitis optica or MOG-IgG-positive encephalomyelitis, two important differential diagnoses of MS. Conclusion MRZR is the most specific laboratory marker of MS reported to date. If present, MRZR substantially increases the likelihood of the diagnosis of MS. Prospective and systematic studies on the diagnostic and prognostic impact of MRZR testing are highly warranted.Keywords
Funding Information
- European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
- European Neurological Society (ENS)
- Bayer HealthCare
- MerckSerono
This publication has 70 references indexed in Scilit:
- Intrathecal, Polyspecific Antiviral Immune Response in Oligoclonal Band Negative Multiple SclerosisPLOS ONE, 2012
- Measles IgG Antibody Index Correlates with T2 Lesion Load on MRI in Patients with Early Multiple SclerosisPLOS ONE, 2012
- Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patientsJournal of Neuroinflammation, 2012
- Usefulness of antibody index assessment in cerebrospinal fluid from patients negative for total-IgG oligoclonal bandsFluids and Barriers of the CNS, 2012
- Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disordersJournal of Neuroinflammation, 2011
- Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysisAnnals of Neurology, 2011
- IgG Antibodies against Measles, Rubella, and Varicella Zoster Virus Predict Conversion to Multiple Sclerosis in Clinically Isolated SyndromePLOS ONE, 2009
- Intrathecal antibody production against Epstein-Barr and other neurotropic viruses in pediatric and adult onset multiple sclerosisJournal of Neurology, 2009
- Differential diagnosis of suspected multiple sclerosis: a consensus approachMultiple Sclerosis Journal, 2008
- Detection of virus-specific intrathecally synthesised immunoglobulin G with a fully automated enzyme immunoassay systemBMC Neurology, 2007